# Massachusetts General Hospital Cancer Center

Source: https://onco.cc/institutions/mgh/  
OnCo record `mgh` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Harvard's largest hospital; leaders in lung cancer targeted therapy, proton therapy, and ctDNA research.

## Summary

Massachusetts General Hospital Cancer Center in Boston is Harvard's largest hospital cancer programme, NCI-designated as comprehensive and sixteenth in the Newsweek/Statista oncology ranking, and it matters most for lung cancer targeted therapy. Its Termeer Center for targeted therapies is the home of its ALK, ROS1 and EGFR resistance research, its Francis H. Burr Proton Center anchors a proton therapy programme, and it holds a Broad Institute affiliation for circulating tumour DNA work. OnCo links it to CAR-T for glioma, to the Sybil lung risk and Mirai breast risk models developed with MIT, to Temel's early palliative care paper, and to the losartan pancreatic cancer idea. The brain as a barrier and sanctuary is the bottleneck its neuro-oncology work confronts. Daniel A. Haber, Keith T. Flaherty, Lecia V. Sequist and Ryan B. Corcoran are among the people listed here.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: Boston, US
- Type: hospital
- NCI designation: comprehensive
- Website: https://www.massgeneral.org/cancer-center

## Sources

- Official website: https://www.massgeneral.org/cancer-center
- PTCOG: particle therapy facilities in operation: https://www.ptcog.site/index.php/facilities-in-operation-public

## Connected records

- technologies: [CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)](https://onco.cc/technologies/glioma-car-t/), [Gamma Knife](https://onco.cc/technologies/gamma-knife/), [Mirai (MIT breast cancer risk from mammograms)](https://onco.cc/technologies/mirai/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Proton therapy machines: cyclotrons, synchrotrons and single-room systems](https://onco.cc/technologies/proton-therapy-systems/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)](https://onco.cc/technologies/radiosurgery-srs/), [Sybil (MIT/MGH lung cancer risk from CT)](https://onco.cc/technologies/sybil/)
- people: [Anthony L. Zietman](https://onco.cc/people/anthony-zietman/), [Constance D. Lehman](https://onco.cc/people/constance-lehman/), [Daniel A. Haber](https://onco.cc/people/daniel-haber/), [Howard L. Kaufman](https://onco.cc/people/howard-kaufman/), [Jennifer S. Temel](https://onco.cc/people/jennifer-temel/), [Justin F. Gainor](https://onco.cc/people/justin-gainor/), [Keith T. Flaherty](https://onco.cc/people/keith-flaherty/), [Lecia V. Sequist](https://onco.cc/people/lecia-sequist/), [Leif W. Ellisen](https://onco.cc/people/leif-ellisen/), [Lori J. Wirth](https://onco.cc/people/lori-wirth/), [Marcela V. Maus](https://onco.cc/people/marcela-maus/), [Matthew R. Smith](https://onco.cc/people/matthew-smith/), [Noopur Raje](https://onco.cc/people/noopur-raje/), [Robert L. Martuza](https://onco.cc/people/robert-martuza/), [Ryan B. Corcoran](https://onco.cc/people/ryan-corcoran/), [Ryan J. Sullivan](https://onco.cc/people/ryan-sullivan/), [Scott R. Plotkin](https://onco.cc/people/scott-plotkin/), [Theodore S. Hong](https://onco.cc/people/theodore-hong/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- key papers: [Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib](https://onco.cc/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/), [ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/), [Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer](https://onco.cc/key-papers/paper-kwak-crizotinib-alk-nsclc-nejm-2010/), [Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status](https://onco.cc/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/), [EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes](https://onco.cc/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/), [Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors](https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/), [MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling](https://onco.cc/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/), [Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer](https://onco.cc/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/), [PARTIQoL: phase 3 randomised trial of proton therapy versus IMRT for localised prostate cancer (ASTRO 2024 late-breaking abstract)](https://onco.cc/key-papers/paper-partiqol-astro-2024/), [Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F](https://onco.cc/key-papers/paper-shaw-alk-l1198f-resensitisation-nejm-2016/), [ROS1 rearrangements define a unique molecular class of lung cancers](https://onco.cc/key-papers/paper-bergethon-ros1-rearrangements-lung-jco-2012/), [Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer](https://onco.cc/key-papers/paper-temel-early-palliative-care-nejm-2010/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [Vivli](https://onco.cc/institutions/vivli/)
- bottlenecks: [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/)
- ideas: [Implant a tiny device that tests twenty drugs inside the patient's own tumour](https://onco.cc/ideas/idea-bio2-implantable-microdevice-screen/), [Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3](https://onco.cc/ideas/idea-reg-losartan-pancreatic-stroma/), [Palliative care from diagnosis for every advanced cancer, including opioid access, worldwide](https://onco.cc/ideas/idea-moon-palliative-care-from-diagnosis-everywhere/)
- pathways: [Hippo-YAP/TAZ](https://onco.cc/pathways/hippo-yap/), [mRNA translation (eIF4F / mTOR)](https://onco.cc/pathways/mrna-translation-eif4f/)
- roadmaps: [Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH](https://onco.cc/roadmaps/radiation-roadmap/)
- trials: [INTUITT-NF2](https://onco.cc/trials/intuitt-nf2/), [NCI-MATCH (EAY131)](https://onco.cc/trials/nci-match/), [PARTIQoL](https://onco.cc/trials/partiqol/)
- companies: [ProTom International](https://onco.cc/companies/protom/)

---
JSON: https://onco.cc/api/v1/entities/mgh.json